drugset
drugset / Trial / NCT06173284

Evaluation of 611(Recombinant Humanized Anti-interleukin-4 Receptor Alpha IgG4 Monoclonal Antibody) in Chinese Adults With Moderate to Severe Atopic Dermatitis

NCT06173284 ↗

Phase 3 Completed 519 enrolled Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The primary objective of the study was to evaluate the efficacy of 611 in Chinese adults with moderate to severe atopic dermatitis.

Timeline

Start
2024-01-22
Primary completion
2025-09-26
Completion
2025-11-20

Drugs

EvaluationDrugModalityDoseRoute
Subject 611 Monoclonal antibody 300 mg Subcutaneous

Indications

atopic eczema